Dr. Heery on Advancements in Treatment of Neuroendocrine Tumors

Christopher Heery, MD
Published: Saturday, Apr 23, 2016



Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors (NETs).

Over the past few years, research has demonstrated that agents used to control the symptoms of NETs could also be used to control disease. Also, Heery says, the combination of radionuclides and other experimental agents may become the backbone of future therapy.

Select subgroups of patients with NETs could also experience positive outcomes with agents such as everolimus (Afinitor) and sunitinib (Sutent).

<<< View more from the 2016 School of Gastrointestinal Oncology



Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors (NETs).

Over the past few years, research has demonstrated that agents used to control the symptoms of NETs could also be used to control disease. Also, Heery says, the combination of radionuclides and other experimental agents may become the backbone of future therapy.

Select subgroups of patients with NETs could also experience positive outcomes with agents such as everolimus (Afinitor) and sunitinib (Sutent).

<<< View more from the 2016 School of Gastrointestinal Oncology


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x